This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Steele, J. P. C. Articles by Rudd, R. M. Search for Related Content PubMed PubMed Citation Articles by Steele, J. P. C. Articles by Rudd, R. M. Social Bookmarking                            What's this?

Phase II Study of Vinorelbine in Patients With Malignant Pleural Mesothelioma

From the Department of Medical Oncology, St Bartholomew’s Hospital, and the London Lung Cancer Group, London, United Kingdom.

Address reprint requests to Jeremy P.C. Steele, MD, MRCP, Department of Medical Oncology, St Bartholomew’s Hospital, West Smithfield, London EC1A 7BE, United Kingdom; email j.p.steele@ mds.qmw.ac.uk.

PURPOSE: To evaluate the response rate and impact on quality of life of vinorelbine given as cycles of 30 mg/m² weekly for 6 weeks to patients with malignant pleural mesothelioma.

PATIENTS AND METHODS: Twenty-nine patients with histologically proven malignant pleural mesothelioma were enrolled (26 male patients and three female patients; median age, 58 years [range, 29 to 77 years]). Seventeen patients had epithelioid tumors, two had sarcomatoid tumors, and 10 had biphasic tumors. The International Mesothelioma Interest Group staging system was used: one patient had stage Ib disease, 10 had stage II disease, eight had stage III disease, and 10 had stage IV disease. Patients were treated with weekly injections of vinorelbine 30 mg/m². A cycle consisted of six weekly injections. The new guidelines to evaluate the response to treatment in solid tumors were used. Responses were measured by spiral computed tomography scan.

RESULTS: All twenty-nine patients had measurable disease and were assessed for response. There were seven partial responses (24% [95% confidence interval, 10% to 44%]), 16 patients had stable disease (55%), and six patients had disease progression on therapy (21%). The median number of vinorelbine injections was 12 (range, 2 to 30). Quality-of-life analyses showed a benefit for vinorelbine therapy.

CONCLUSION: Vinorelbine shows promise in the palliation of patients with malignant pleural mesothelioma. The relatively low toxicity of the drug suggests that trials of vinorelbine in combination with other agents should be feasible.

The authors acknowledge the support of Pierre-Fabre Oncology for subsidized drug costs.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Ray and H. L. Kindler Malignant Pleural Mesothelioma: An Update on Biomarkers and Treatment Chest, September 1, 2009; 136(3): 888 - 896. [Abstract] [Full Text] [PDF]

				A. S. Tsao, I. Wistuba, J. A. Roth, and H. L. Kindler Malignant Pleural Mesothelioma J. Clin. Oncol., April 20, 2009; 27(12): 2081 - 2090. [Abstract] [Full Text] [PDF]

				M. de Perrot, R. Feld, B.C. J. Cho, A. Bezjak, M. Anraku, R. Burkes, H. Roberts, M. S. Tsao, N. Leighl, S. Keshavjee, et al. Trimodality Therapy With Induction Chemotherapy Followed by Extrapleural Pneumonectomy and Adjuvant High-Dose Hemithoracic Radiation for Malignant Pleural Mesothelioma J. Clin. Oncol., March 20, 2009; 27(9): 1413 - 1418. [Abstract] [Full Text] [PDF]

				H. L. Kindler, R. Bueno, and J. R. Testa New Biomarkers, Surgical Controversies, and Rationally Targeted Therapies for Malignant Mesothelioma ASCO Educational Book, January 1, 2008; 2008(1): 354 - 361. [Abstract] [Full Text] [PDF]

				British Thoracic Society Standards of Care Committ BTS statement on malignant mesothelioma in the UK, 2007 Thorax, November 1, 2007; 62(Suppl_2): ii1 - ii19. [Full Text] [PDF]

				W Weder, R. Stahel, J Bernhard, S Bodis, P Vogt, P Ballabeni, D Lardinois, D Betticher, R Schmid, R Stupp, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma Ann. Onc., July 1, 2007; 18(7): 1196 - 1202. [Abstract] [Full Text] [PDF]

				G. L. Ceresoli, C. Gridelli, and A. Santoro Multidisciplinary Treatment of Malignant Pleural Mesothelioma Oncologist, July 1, 2007; 12(7): 850 - 863. [Abstract] [Full Text] [PDF]

				L. L. Garland, C. Rankin, D. R. Gandara, S. E. Rivkin, K. M. Scott, R. B. Nagle, A. J.P. Klein-Szanto, J. R. Testa, D. A. Altomare, and E. C. Borden Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study J. Clin. Oncol., June 10, 2007; 25(17): 2406 - 2413. [Abstract] [Full Text] [PDF]

				Can {blacktriangledown}pemetrexed help in malignant mesothelioma? DTB, October 1, 2006; 44(10): 77 - 80. [Abstract] [Full Text] [PDF]

				R. Maruyama, M. Sakai, T. Nakamura, R. Suemitsu, T. Okamoto, H. Wataya, K. Nishiyama, T. Kamei, and Y. Ichinose Triplet Chemotherapy for Malignant Pericardial Mesothelioma: A Case Report Jpn. J. Clin. Oncol., April 1, 2006; 36(4): 245 - 248. [Abstract] [Full Text] [PDF]

				S. G. Armato III, J. L. Ogarek, A. Starkey, N. J. Vogelzang, H. L. Kindler, M. Kocherginsky, and H. MacMahon Variability in mesothelioma tumor response classification. Am. J. Roentgenol., April 1, 2006; 186(4): 1000 - 1006. [Abstract] [Full Text] [PDF]

				M. E. R. O'Brien, D. Watkins, C. Ryan, K. Priest, C. Corbishley, A. Norton, S. Ashley, N. Rowell, and R. Sayer A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial Ann. Onc., February 1, 2006; 17(2): 270 - 275. [Abstract] [Full Text] [PDF]

				R. Maruyama, F. Shoji, T. Okamoto, T. Miyamoto, T. Miyake, T. Nakamura, J. Ikeda, Y. Aoki, H. Wataya, H. Asoh, et al. Triplet Chemotherapy with Cisplatin, Gemcitabine and Vinorelbine for Malignant Pleural Mesothelioma Jpn. J. Clin. Oncol., August 1, 2005; 35(8): 433 - 438. [Abstract] [Full Text] [PDF]

				J. P. C. Steele and A. Klabatsa Chemotherapy options and new advances in malignant pleural mesothelioma Ann. Onc., March 1, 2005; 16(3): 345 - 351. [Abstract] [Full Text] [PDF]

				D. A. Fennell, A. Parmar, J. Shamash, M. T. Evans, M. T. Sheaff, R. Sylvester, K. Dhaliwal, N. Gower, J. Steele, and R. Rudd Statistical Validation of the EORTC Prognostic Model for Malignant Pleural Mesothelioma Based on Three Consecutive Phase II Trials J. Clin. Oncol., January 1, 2005; 23(1): 184 - 189. [Abstract] [Full Text] [PDF]

				M. Pistolesi and J. Rusthoven Malignant Pleural Mesothelioma: Update, Current Management, and Newer Therapeutic Strategies Chest, October 1, 2004; 126(4): 1318 - 1329. [Abstract] [Full Text] [PDF]

				W. Weder, P. Kestenholz, C. Taverna, S. Bodis, D. Lardinois, M. Jerman, and R. A. Stahel Neoadjuvant Chemotherapy Followed by Extrapleural Pneumonectomy in Malignant Pleural Mesothelioma J. Clin. Oncol., September 1, 2004; 22(17): 3451 - 3457. [Abstract] [Full Text] [PDF]

				E. Andreopoulou, P. J. Ross, M. E. R. O'Brien, H. E. R. Ford, K. Priest, T. Eisen, A. Norton, S. Ashley, and I. E. Smith The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma Ann. Onc., September 1, 2004; 15(9): 1406 - 1412. [Abstract] [Full Text] [PDF]

				A. K. Nowak, M. R. Stockler, and M. J. Byrne Assessing Quality of Life During Chemotherapy for Pleural Mesothelioma: Feasibility, Validity, and Results of Using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module J. Clin. Oncol., August 1, 2004; 22(15): 3172 - 3180. [Abstract] [Full Text] [PDF]

				C. D. Hoang, J. D'Cunha, M. G. Kratzke, C. E. Casmey, S. P. Frizelle, M. A. Maddaus, and R. A. Kratzke Gene Expression Profiling Identifies Matriptase Overexpression in Malignant Mesothelioma Chest, May 1, 2004; 125(5): 1843 - 1852. [Abstract] [Full Text] [PDF]

				M F Muers, R M Rudd, M E R O'Brien, W Qian, A Hodson, M K B Parmar, and D J Girling BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112 Thorax, February 1, 2004; 59(2): 144 - 148. [Abstract] [Full Text] [PDF]

				J P C Steele The new front line treatment for malignant pleural mesothelioma? Thorax, February 1, 2003; 58(2): 96 - 97. [Full Text]

				P. A. Janne, M. L. Taffaro, R. Salgia, and B. E. Johnson Inhibition of Epidermal Growth Factor Receptor Signaling in Malignant Pleural Mesothelioma Cancer Res., September 15, 2002; 62(18): 5242 - 5247. [Abstract] [Full Text] [PDF]

				A. Hughes, P. Calvert, A. Azzabi, R. Plummer, R. Johnson, J. Rusthoven, M. Griffin, K. Fishwick, A. V Boddy, M. Verrill, et al. Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma J. Clin. Oncol., August 15, 2002; 20(16): 3533 - 3544. [Abstract] [Full Text] [PDF]